US › Healthcare

Whitehawk Therapeutics, Inc. (WHWK)

US · Healthcare · Biotechnology

$4.14+4.55%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-22.2M
Profit YoY
-130.4%
EPS
$-0.32
EPS estimate
$-0.33

EPS came in at -0.32 against a street estimate of -0.33 — a beat of 3.0%.

Key statistics

Market cap
$195.8M
Forward P/E
2.7
P/B
1.64
Book value
$2.46
EPS (TTM)
$-2.49
52-week high
$5.50
52-week low
$1.57
50-day MA
$4.14
200-day MA
$3.31
Beta
0.78

Analyst view

Analysts rate Whitehawk Therapeutics, Inc. a hold (0 buy, 3 hold, 0 sell out of 3) with an average price target of $7.50.

Shareholding

Insiders
13.38%
Institutions
73.27%

Largest institutional holders

FundStake
Qvt Financial LP9.33%
Orbimed Advisors, LLC8.42%
Suvretta Capital Management, LLC7.48%
Longwood Capital Partners LLC6.90%
venBio Select Advisor LLC5.76%
KVP Capital Advisors, LP4.38%
Siren, L.L.C.4.21%
Yu Fan4.19%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Whitehawk Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.